01 8Genvoya
02 5Stribild
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 196
2019 Revenue in Millions : 369
Growth (%) : -47
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 3,338
2019 Revenue in Millions : 3,931
Growth (%) : -15
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 189
2020 Revenue in Millions : 196
Growth (%) : -4
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 2,879
2020 Revenue in Millions : 3,338
Growth (%) : -14
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2022 Revenue in Millions : 127
2021 Revenue in Millions : 189
Growth (%) : -33
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2022 Revenue in Millions : 2,404
2021 Revenue in Millions : 2,879
Growth (%) : -16
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2023 Revenue in Millions : 2,060
2022 Revenue in Millions : 2,404
Growth (%) : -14
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2023 Revenue in Millions : 101
2022 Revenue in Millions : 127
Growth (%) : -20
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alafenamide
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alaf...
Main Therapeutic Indication : Infectious Diseases (HIV, Hepatitis...
Currency : USD
2015 Revenue in Millions : 0
2014 Revenue in Millions : 45
Growth (%) : New Launch
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alaf...
Main Therapeutic Indication : Infectious Diseases (HIV, Hepatitis...
Currency : USD
2017 Revenue in Millions : 3,674
2016 Revenue in Millions : 1,484
Growth (%) : 148
LOOKING FOR A SUPPLIER?